For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Agy Therapeutics, Inc.

Calculating rank

USPTO Granted Patents = 13

% Expired Patents = 46.2

Forward Citations = 214

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Daniel J Chin (8 out of 11 patents)

Thorsten Melcher (7 out of 7 patents)

Mirella Gonzalez-Zulueta (4 out of 5 patents)

4. Sabine Mueller (3 out of 4 patents)

5. Tadeusz Wieloch (2 out of 3 patents)

6. Li Gan (2 out of 10 patents)

7. Donna Hendrix (2 out of 2 patents)

8. Kalev Kask (2 out of 2 patents)

9. Keith McFarland (1 out of 18 patents)

10. Roman Urfer (1 out of 5 patents)

11. Erik Damien Foehr (1 out of 5 patents)

12. Richa Wilson (1 out of 9 patents)

13. Donna Oksenberg (1 out of 3 patents)

14. Shu-Gui Huang (1 out of 1 patent)

15. Shiming Ye (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 7060275 - Use of protein biomolecular targets in the treatment and visualization of brain tumors (2006-06-13),

2. 7014838 - Use of biomolecular targets in the treatment and visualization of brain tumors (2006-03-21),

3. 6977142 - High-throughput turbidometric assay for screening inhibitors of protein disulfide isomerase activity (2005-12-20),

4. 6924109 - High-throughput transcriptome and functional validation analysis (2005-08-02),

5. 6876930 - Automated pathway recognition system (2005-04-05),

6. 6846641 - In vitro ischemia model (2005-01-25),

7. 6841351 - High-throughput transcriptome and functional validation analysis (2005-01-11),

8. 6670138 - Method of diagnosing ischemic stroke via UCP-2 detection (2003-12-30),

9. 6660483 - Diagnostic marker for neurological conditions (2003-12-09),

10. 6586239 - Purifying microglial cells by binding cell Fc receptor to immunoglobulin G Fc domain (2003-07-01),

11. 6521414 - Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1 (2003-02-18),

12. 6470277 - Techniques for facilitating identification of candidate genes (2002-10-22),

13. 6455026 - Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors (2002-09-24),

Company Overview

Agy Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for neurodegenerative diseases. The organization specializes in harnessing advanced molecular technologies to create treatments that target underlying disease mechanisms. Agy Therapeutics aims to address significant unmet medical needs through its research initiatives, leveraging expertise in drug discovery and development to improve patient outcomes in the field of neurology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

13 Patents

#90 in South San Francisco, CA

#5,664 in California

#23,863 in US

#45,104 in the World

South San Francisco, CA, United States of America

Agy Therapeutics, Inc.

Forward Citations = 214

24 inventors:

Daniel J Chin (8 out of 11 patents)

Thorsten Melcher (7 out of 7 patents)

Mirella Gonzalez-Zulueta (4 out of 5 patents)

4. Sabine Mueller (3 out of 4 patents)

5. Tadeusz Wieloch (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Agy Therapeutics, Inc.. Retrieved from https://idiyas.com/company/agy-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…